Delivery Order SPE2DB20D1100-SPE2DB25FE3V0
- Not listed
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a $19,064.54 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injections on July 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, was competitively awarded with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary...
- The Defense Logistics Agency (DLA) awarded a $1,172.10 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (tirzepatide) 5 mg/0.5 mL pen injections on July 22, 2025, with completion expected by July 23, 2025. This competitively awarded, non-set-aside contract represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The work will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $34,076.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pen injectors. This non-competitive, non-set-aside delivery order is scheduled for ultimate completion on July 29, 2025, with performance taking place at the contractor's corporate office in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's critical role as a pharmaceutical...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $9,800.70 on July 31, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors. This firm fixed-price delivery order, which is not set-aside for any small business category, will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 1, 2025. The contract represents a child delivery order under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,143.89 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL injectable pens. This competitively awarded, firm fixed-price delivery order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. No set-aside designation was applied to this award. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pen injectors valued at $3,911.93, with performance through August 25, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order valued at $11,057.47 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 ml pen injections on August 8, 2025. This firm fixed-price delivery order, with a completion date of August 11, 2025, was competitively awarded with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pre-filled pens. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE3V0Delivery Order
The Defense Logistics Agency awarded a $3,431.65 delivery order to AmerisourceBergen Drug Corp for ZEPBOUND (tirzepatide) 5 mg/0.5 mL pen injectors on August 29, 2025. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 2, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation and represents a child contract under the company's larger federal contract vehicle. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor headquartered in Pennsylvania, is a critical federal vendor for medical supply procurement supporting the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's federal contract portfolio demonstrates extensive experience delivering brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains through competitively awarded delivery orders with firm fixed pricing.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 8/29/25 |